Purpose: This retrospective analysis study aimed to assess the short to medium term haemodynamic outcomes and durability of the Perceval sutureless valve (Livanova) at an Australian institution. Methodology: Patients undergoing sutureless aortic valve replacement (SU-AVR) between 2014-2022 at the Alfred Hospital were included. Haemodynamic performance of the SU-AVR was assessed by obtaining echocardiogram reports. Mean aortic effective orifice area (EOA, cm2), mean transaortic pressure gradient (mmHg) and left ventricular mass (g) were investigated. The medium-term durability (structural valve deterioration) of the Perceval valve was also examined. Results: Seventy-three patients underwent SU-AVR. Fifteen patients were lost to follow-up. Mean follow-up was 36.93 ± 23.28 months in 58 patients. Follow-up data was collected up to 72 months. Isolated AVR was performed in 34 patients (46.58%) and CABG+AVR was performed in 36 patients (49.32%). Mean (± SD) cardiopulmonary-bypass time was 83.2 ± 36.8 minutes, and aortic cross clamp time 59.2 ± 32.1 minutes. There was one case of SVD causing aortic stenosis and two cases of major paravalvular leak. Five explants were performed (PVL; n=2, IE; n=2, SVD; n=1). Pre-operative mean gradient was 40.55 ± 18.02 mmHg. At 36 months, the gradients remained low at 11.25±4.74 mmHg. Left ventricular remodelling occurred as demonstrated by a mean LV mass of 248.34±68.6 g preoperatively and 200.0±47.57 g at 36 months. The mean aortic EOA was 0.948 ± 0.48 cm2 pre-operatively and 1.86±0.43 cm2 ¬at 36 months. Seven mortalities were recorded, with causes attributed to sepsis (n=1, 1.37%), endocarditis (n=5, 6.85%) and withdrawal of VAD (n=1, 1.37%). Morbidity included stroke (n=2), renal insufficiency (n=6), pneumonia (n=8) and return to theatre for bleeding (n=5). Conclusion: The deployment of the Perceval S Bioprosthesis valve has a low rate of structural valve deterioration and excellent haemodynamic performance at a mean of 36 months of follow-up.